Keros Therapeutics, Inc. (KROS) — QMA analysis
Sector: Healthcare · Data as of Nov 4, 2026
Price and market data
Keros Therapeutics, Inc. has a below-average composite score of 34/100, higher score than 18% of 21,569 securities in the comparison. The highest-scoring layer is Analysts / transcripts; the lowest is Catalysts.
What 10 data layers say about KROS
The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.
| Layer | Score |
|---|---|
| Fundamental value (FVS) | 41/100 |
| Earnings quality (EQS) | 5/100 |
| Technical trend (TSS) | 47/100 |
| Relative strength (RS) | 40/100 |
| Momentum (USS) | 43/100 |
| Insider activity (IAS) | 21/100 |
| Off-exchange trading (FINRA) / large flows (WHS) | 48/100 |
| Institutional 13F (IFS) | 56/100 |
| Analysts / transcripts (ATS) | 77/100 |
| Catalysts (XS) | 4/100 |
What does the QMA model currently show for Keros Therapeutics, Inc.?
The composite score is an entry point, not a signal. What matters is layer confluence — whether they point the same direction.
For KROS the layers diverge — some score high (Analysts / transcripts), others low (Catalysts). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.
KROS insider & smart money activity
Over the recent period we record 3 reported insider purchases and 12 sales for KROS: predominance of reported sales (by dollar value). A description of the data layer, not an instruction.
KROS seasonality
KROS is currently in its seasonal window November 1–28 with a hit rate of 67% and an average move of 15.3% (7 years of history; selected in hindsight, descriptive, not a prediction).
Historical data does not guarantee future results.
How KROS compares
Similar stocks from the same sector:
Frequently asked questions
What is the composite score for KROS stock?
34/100 (grade F) as of Nov 4, 2026, fusing 10 data layers. An analytical score, not advice.
Are insiders buying KROS stock?
Over the recent period, reported: purchases 3, sales 12 (purchases $183K, sales $3.09M). Insider activity: predominance of reported sales (by dollar value) — a description of reported data, not a trade instruction.
Where can I see live KROS data?
Price and market data for KROS are shown on paid plans; the QMA scores and grades on this page are free. Registration is free with no card — trial full access, then the free plan.
Explore more — for free
The KROS score is just the start. Keep going free in the QMA magazine — analysis, tools and learning with no payment up front.
Want the full KROS analysis with all layers and live data? Open KROS detail →
Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.
⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.
Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: support@quantummarketanalyzer.com